NEW YORK, May 21 (Reuters) - Cigna (CI.N), opens new tab will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans, the company announced on ...

Evernorth — the Cigna division that oversees the Express ... monthly copays for two popular weight-loss drugs, Wegovy and Zepbound, at $200. The impact on the employers' spending is unclear ...

The Cigna unit positioned the initiative as a cheaper alternative to cash-pay programs. Wegovy maker Novo Nordisk and Zepbound manufacturer Eli Lilly directly sell their drugs to certain patients ...

The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

After taking Zepbound for a year ... managers together control 80 percent of the prescription market. The others, Cigna’s Express Scripts and UnitedHealth’s Optum Rx, have not taken similar ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Evernorth, the pharmacy benefits unit for health insurer giant Cigna, has reached a deal with ... copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200.

Cigna Group’s drug benefit unit is offering ... patients would pay less than the cash price for Eli Lilly & Co.’s Zepbound or Novo Nordisk A/S’s Wegovy, but typically more than the normal ...